Best Current Therapeutic Updates Podcasts (2024)

1
Scaling Allo with Allogene Therapeutics' Dr. Zachary Roberts 25:13

2h ago25:13

25:13

We love to hear from our listeners. Send us a message. Allogene Therapeutics' EVP of R&D and CMO, Dr. Zachary Roberts, penned an original article for Cell & Gene titled, The Path Forward for CLL is Allogeneic. In his article, Dr. Roberts explains that chronic lymphocytic leukemia (CLL) is the most common leukemia in the U.S. And that while CLL rema…

1
ROS1-Alterations and Molecular Testing in Advanced NSCLC 16:28

5h ago16:28

16:28

In this episode, listen to Alice T. Shaw, MD, PhD, and Jessica J. Lin, MD, share their thoughts on the current understanding of ROS1 rearrangements in non-small-cell lung cancer tumor biology and its implications for molecular testing and treatment selection including: ROS1-gene fusions in advanced lung cancer ROS1 testing recommendations with DNA …

1
Inside the Issue: Integrating ALK-Targeted Therapy into the Management of Localized Non-Small Cell Lung Cancer 1:01:23

1h ago1:01:23

1:01:23

Prof Solange Peters from the Lausanne University Hospital in Lausanne, Switzerland, and Professor Ben Solomon from the Peter MacCallum Cancer Centre in Melbourne, Australia, discuss treatment approaches for ALK-rearranged non-small cell lung cancer in the localized disease setting.By Neil Love, MD

1
Navigating the Complexities of Sickle Cell Disease: An Expert Perspective

10d ago

—

Host: Jennifer Caudle, DO Guest: Samuel R. Wilson, MD Sickle cell disease is among the most common inherited conditions globally, affecting more than seven million individuals worldwide.1-3 Given its prevalence, it is important to understand all of the complexities surrounding this disease. Joining Dr. Jennifer Caudle to discuss the pathophysiology…

1
CGT Regulatory Update and Outlook with Dark Horse Consulting's Kimberly Benton, Ph.D. 27:58

14d ago27:58

27:58

We love to hear from our listeners. Send us a message. Applications (BLAs) of recent approvals and complete responses for novel products or rare diseases as well as BLAs currently under review. Benton shares information about FDA Draft Gudiances, including Platform Technology Designation Program for Drug Development: Guidance for Industry. She also…

1
Oncology Today with Dr Neil Love: Novel Agents and Strategies in Lung Cancer 1:01:43

2h ago1:01:43

1:01:43

Dr Melissa Johnson from Sarah Cannon Research Institute in Nashville, Tennessee, Dr Ticiana Leal from Winship Cancer Institute of Emory University in Atlanta, Georgia, and Dr Manish Patel from Florida Cancer Specialists & Research Institute in Sarasota, Florida, summarize recently presented advancements, including novel strategies, in the treatment…

1
Beyond Single-Cancer Screens: Unveiling Progress in Early Detection Testing

25d ago

—

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Jessie Hsieh, MD Guest: David Isaacson, MD About 70 percent of all cancer-related deaths are associated with cancers that don't have recommended USPSTF screening modalities.1 But the good news is that adding multicancer early detection (MCED) testing to usual care screenings could help address this ga…

1
Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Immunotherapy and Other Nontargeted Approaches for Lung Cancer 1:00:53

17d ago1:00:53

1:00:53

Dr Matthew Gubens from the University of California, San Francisco summarizes important 2023 datasets guiding the use of immunotherapy and other nontargeted approaches for patients with NSCLC and no actionable mutations.By Neil Love, MD

1
Midyear Highlights of Key Data From 2024 Gynecologic Cancer Conferences Informing Treatment of Ovarian, Endometrial, and Cervical Cancers 49:32

16d ago49:32

49:32

In this episode, listen to Floor J. Backes, MD, and Angeles Alvarez Secord, MD, MHSc, share their clinical insights and takeaways on new data presented for endometrial, ovarian, and cervical cancers presented at the 2024 annual meetings of the Society of Gynecologic Oncology and American Society of Clinical Oncology including: RUBY Part 1 Subgroup …

1
Identifying Drug Development Opportunities for DMD with CureDuchenne 29:55

30d ago29:55

29:55

We love to hear from our listeners. Send us a message. Debra Miller, CEO and Founder and Dr. Michael Kelly, Chief Scientific Officer at CureDuchenne talk to Host Erin Harris about the FDA approval for the expansion to the label indication for ELEVIDYS from Sarepta Therapeutics as well as how CureDuchenne works with various biotechs developing gene …

1
Navigating How the Updated ASCCP Guidelines Can Work for You

1M ago

—

Host: Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA Guest: Leigh Anne Cantrell, MD, MSPH The updated ASCCP guidelines now address the use of dual-stain technology for cervical cancer management. CINtec PLUS Cytology is a test for the co-expression of p16 and Ki67 and confirms the presence of a transforming HPV infection and defines patients with …

1
Oncology Today with Dr Neil Love: An interview with Jonathan W Goldman, MD — Management of Non-Small Cell Lung Cancer with an EGFR Mutation 47:34

1M ago47:34

47:34

Dr Jonathan W Goldman from UCLA Health in Santa Monica, California summarizes recent developments presented at ASCO 2024 for patients with non-small cell lung cancer with an EGFR mutation.By Neil Love, MD

1
Next-Generation Therapeutics for HR+/HER2- Breast Cancer: Spotlight on SERDs 34:45

22d ago34:45

34:45

In this episode, Dr Virginia Kaklamani moderates a discussion with Dr Aditya Bardia and Dr Sarah Sammons answering audience questions on the latest data on the use of oral SERDs therapy, including how to incorporate this new class of therapy into treatment plans for patients with HR+/HER2- breast cancer. Presenters: Virginia Kaklamani, MD, DSc Prof…

1
Current Clinical Practice and NCCN Guidelines for CLL/SLL 31:33

1M ago31:33

31:33

In this podcast episode, Farrukh Awan, MD, Jeremy S. Abramson, MD, MMSc, and Shuo Ma, MD, PhD, discuss real-world patient cases and how to align current clinical practice with the NCCN guidelines for CLL/SLL, including: Prognostic variables when deciding between regimens Role of MRD in CLL Results from the phase II CAPTIVATE trial Choosing among th…

1
Tackling "The Delivery Problem" of Gene Editing-Based Medicines with Mammoth Biosciences' Lucas Harrington 21:01

26d ago21:01

21:01

We love to hear from our listeners. Send us a message. Lucas Harrington, Co-Founder and Chief Scientific Officer of Mammoth Biosciences, joins Erin Harris to shed light on the biotech's proprietary ultracompact CRISPR systems to develop potential long-term curative therapies for patients with life-threatening and debilitating diseases. They discuss…

1
Congress to Clinic: Expert Takeaways on Emerging Data for MPNs 28:35

1M ago28:35

28:35

In this episode, listen to Dr Brady L. Stein share his clinical insights and takeaways on new data for myeloproliferative neoplasms (MPNs) presented at the 2024 ASCO Annual Meeting and the EHA 2024 Congress including: Long-term survival adjusted for treatment crossover in patients with myelofibrosis (MF) treated with momelotinib vs danazol in the M…

1
CELMoDs: Spotlight on Therapeutic Approaches Targeting Protein Degradation Pathways 24:23

1M ago24:23

24:23

In this podcast episode, Julio C. Chavez, MD, MS, and Alan Skarbnik, MD, discuss the emerging role of CELMoDs in NHL care, including: Rationale for targeting CELMoDs in NHL Mechanism of action of CELMoDs Key studies and available efficacy and safety data with investigational CELMoDs in NHL Key ongoing clinical trials of CELMoDs in NHL Strategies to…

1
Experts Discuss the Role of CDK4/6 Inhibitors in HR+/HER2- Breast Cancer 24:30

1M ago24:30

24:30

In this episode, Dr Joyce O’Shaughnessy moderates a discussion with Dr Sara Hurvitz and Dr Erica Mayer answering audience questions on the latest data on incorporating CDK4/6 inhibitors into treatment plans for patients with HR+/HER2- breast cancer. Topics in this podcast include: Evidence from the monarchE and NATALEE trials of adjuvant abemacicli…

1
Importance of a Timely Postpartum Depression Diagnosis: Patient Perspectives

2M ago

—

Host: Matt Birnholz, MD Guest: Kay Matthews, LCHW Ms. Kay Matthews has lived experience with postpartum depression and now advocates for others as the Executive Director and Founder of Shades of Blue, which is dedicated to breaking cultural barriers in maternal mental health. Tune in to hear her speak with Dr. Matt Birnholz about her journey with p…

1
Congress to Clinic: Expert Takeaways on Emerging Data for AML 25:21

1M ago25:21

25:21

In this episode, listen to Professor Eunice S. Wang, MD, share her clinical insights and takeaways on new data for acute myeloid leukemia (AML) presented at the 2024 ASCO annual meeting and the EHA 2024 Congress including: Data from the prospective, single-center phase Ib/II study of FLAG-IDA plus venetoclax in newly diagnosed or relapsed/refractor…

1
Congress to Clinic: Expert Takeaways on Emerging Data for MDS 19:19

1M ago19:19

19:19

In this episode, listen to Professor Courtney DiNardo, MD, MSCE, share her clinical highlights and clinical takeaways on new data for myelodysplastic syndromes (MDS) presented at the 2024 ASCO annual meeting and the EHA 2024 Congress including: COMMANDS trial of luspatercept in transfusion-dependent, erythropoietin stimulating agent–naive, very low…

1
TILs for the Treatment of Solid Tumors with KSQ Therapeutics' Micah Benson, Ph.D. 35:30

2M ago35:30

35:30

We love to hear from our listeners. Send us a message. KSQ Therapeutics' CSO, Micah Benson, Ph.D., joins Erin Harris to discuss how Tumor-Infiltrating Lymphocytes (TILs) as a treatment modality have the potential to treat a variety of solid tumor types. Benson explains KSQ's Phase 1/2 clinical study, KSQ-001EX, which consists of TILs in which the S…

1
Synthetic Biology and Programmable mRNA with Strand Therapeutics' Jake Becraft 27:52

2M ago27:52

27:52

We love to hear from our listeners. Send us a message. Strand Therapeutics' CEO and Co-Founder Jake Becraft joins Erin Harris to discuss genetic regulation and how the company's programmable mRNA constructs combine genes for self-replication derived from RNA viruses with genetically programmed logic circuits that control the location, timing, and i…

1
Treating Breakthrough PONV: A Review of Therapeutic Approaches, Considerations, and Guidelines

3M ago

—

Guest: TJ Gan, MD, MBA, MHS, FRCA (UK), FRCA (lre), LicAc Guest: Dru Riddle, PhD, DNP, CRNA When it comes to postoperative nausea and vomiting (PONV) management, multimodal, antiemetic therapy based on patients’ risk factors is routinely provided to minimize the incidence, but unfortunately, patients may still develop breakthrough PONV, in which an…

1
Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Targeted Therapy for Non-Small Cell Lung Cancer 1:00:48

3M ago1:00:48

1:00:48

Dr Justin F Gainor from Massachusetts General Hospital in Boston and Dr Karen Reckamp from Cedars-Sinai Center in Los Angeles, California, summarize recently presented data on targeted therapy strategies for non-small cell lung cancer harboring actionable therapeutic targets.By Neil Love, MD

1
Developing an mRNA Therapy for DMD with Elixirgen Therapeutics' Aki Ko 14:52

3M ago14:52

14:52

We love to hear from our listeners. Send us a message. Elixirgen Therapeutics' Aki Ko joins Erin Harris to detail the company's Bobcat mRNA therapeutic and how it differs from traditional exon-skipping drugs and AAV-microdystrophin in treating DMD. Regarding delivery, Ko explains the advantage of the mRNA approach over the AAV approach.…

1
An Introduction to Squamous Cell Carcinoma of the Head and Neck

3M ago

—

Guest: Lori J. Wirth, MD Head and neck cancers are the seventh most common cancers globally and are increasing in prevalence.1,2 To dive further into the intricacies of this early-stage cancer, join Dr. Lori Wirth, Medical Oncologist in the Head and Neck Oncology Program at Massachusetts General Hospital in Boston. References: Gormley M, et al. Br …

1
EMERALD Trial: An Analysis of Key Biomarkers and Patient Subgroups

3M ago

—

Host: Jennifer Caudle, DO Guest: Joyce O'Shaughnessy, MD The results from the phase III EMERALD trial led to the approval of ORSERDU® (elacestrant) as the first oral selective estrogen receptor degrader for ER-positive/HER2-negative metastatic breast cancer patients with ESR1 mutations after disease progression following at least one line of endocr…

1
The Value of CINtec® PLUS Cytology Test in Cervical Cancer Screening

3M ago

—

Host: Jennifer Caudle, DO Guest: Tamera A. Paczos, MD, FACOG, FACP The utility of p16 and Ki-67 immunostaining in biopsies has helped lead to the development of dual staining in cytology specimens. So what do clinicians need to know about the dual stain cytology test? Take a deep dive into this topic as Dr. Jennifer Caudle is joined by Dr. Tamera A…

1
The Current State of the Global Regulatory Landscape with ISCT's Dr. Bambi Grilley 25:21

3M ago25:21

25:21

We love to hear from our listeners. Send us a message. Dr. Bambi Grilley is Professor of Pediatrics and the Director of Clinical Research and Early Product Development for the Center of Cell and Gene Therapy (CAGT) at Baylor College of Medicine AND she is Chief Regulatory Officer at ISCT. Dr. Grilley talks to us about her role as CRO at ISCT and th…

1
Dr. Bruce Levine on ISCT and the Future of CAR-T 31:49

3M ago31:49

31:49

We love to hear from our listeners. Send us a message. In anticipation of ISCT 2024 in Vancouver, Canada, Dr. Bruce Levine is back on Cell & Gene: The Podcast to share information about the event as well as his expertise on the future of CAR-T therapy for solid tumors, autoimmune disease, and more. He talks about his time and learnings as President…

1
Diagnostic and Treatment Dilemmas in Polymyalgia Rheumatica

3M ago

—

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: William F.C. Rigby, MD Polymyalgia rheumatica (PMR) is an inflammatory rheumatic condition that can be difficult to diagnose and treat. For instance, PMR is a diagnosis of exclusion, and it can mimic a wide variety of other conditions. And once a patient is accurately diagnosed, the standard-of-care t…

1
Investigating HLH: Our Current Understanding of a Rare Disease

4M ago

—

Guest: Adam Narloch Guest: Michelle Hermiston, MD, PhD Adam Narloch speaks with Dr Michelle Hermiston to discuss the history of hemophagocytic lymphohistiocytosis (HLH) and advances in understanding this rare disease. Dr Hermiston is a pediatric hematologist-oncologist, a bone marrow transplant specialist, and the Director of the Pediatric Immunoth…

1
Experiences With Oral SERDs for HR+/HER2- Metastatic Breast Cancer 25:55

3M ago25:55

25:55

In this episode, Manali Bhave, MD; Annalise Labatut, PharmD, BCOP; and nurse practitioner Jamie L. Carroll, CNP, APRN, MSN, begin by discussing the landmark EMERALD study that led to FDA approval of elacestrant, the first oral selective estrogen receptor degrader (SERD) for treatment of hormone receptor–positive/HER2-negative metastatic breast canc…

1
CGTs for HIV Suppression with Addimmune's Dr. Marcus Conant 18:51

4M ago18:51

18:51

We love to hear from our listeners. Send us a message. Dr. Marcus Conant is CMO at Addimmune, a biotech startup developing a cell therapy for HIV that spun out of cell and gene therapy biotech American Gene Technologies (AGT). He spent his career on the front lines of HIV treatment and research and remains an advocate for the HIV patient. He formed…

1
Applying the Latest Evidence and NCCN Guideline Recommendations in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 47:23

3M ago47:23

47:23

In this episode, Danielle M. Brander, MD; Deborah Stephens, DO; and Brian Hill, MD, PhD, discuss key aspects of the NCCN CLL guidelines and share strategies for applying these recommendations in your clinical practice to optimize treatment and outcomes. The greater discussion addresses: Optimal selection of therapy for treatment-naive CLL, includin…

1
Inside BlueRock Therapeutics' Parkinson's Disease Trial with Dr. Ahmed Enayetallah 29:39

4M ago29:39

29:39

We love to hear from our listeners. Send us a message. BlueRock Therapeutics' SVP Head of Development, Dr. Ahmed Enayetallah, joins Cell & Gene: The Podcast Host, Erin Harris, to discuss the company's phase I clinical trial for Parkinson’s disease, which continues to show positive trends at 18 months. They cover the important role induced pluripote…

1
Experts on the Ground: Data Updates on Emerging Therapies for IgAN

4M ago

—

Host: Richard Lafayette, MD, FACP Expert Nephrologist Richard Lafayette, MD, FACP, gives an overview of top abstracts from Kidney Week 2023 and updates on emerging therapies for IgAN.

1
Delivering Transformation: Reducing Maternal Mortality Through Systemic Change

5M ago

—

Guest: Dena Goffman, MD Dr. Dena Goffman believes that better maternal care requires a proactive, system-wide approach and is making her vision a reality at NewYork-Presbyterian. She focuses on implementing guidelines that standardize care across all of NewYork-Presbyterian’s hospitals. Dr. Goffman has also aided in FDA approval and adoption of a n…

1
The Gene Messenger: Advancing Neurological Gene Therapy

5M ago

—

Guest: Michael Kaplitt, MD, PhD For the first time, Dr. Michael Kaplitt was able to perform a trial for a neurological gene therapy that was administered in a human patient to address damaged brain cells caused by Parkinson’s disease. This procedure used an adeno-associated virus to deliver a gene into the brain of a patient with Parkinson’s. The r…

1
Deep Learner: Building AI to Improve Cardiovascular Care

5M ago

—

Guest: Pierre Elias, MD In this episode, you’ll gain insights into Dr. Elias’ innovative approach, integrating technology, data science, and medicine to develop algorithms that aim to enhance accuracy in predicting cardiovascular disease while allowing them to focus on providing personalized care to their patients. This could even help diagnose pat…

1
Severe Asthma: An Exploratory Study on Mucus Plugging

5M ago

—

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Arnaud Bourdin, MD, PhD Since many severe asthma patients have been shown to have mucus plugs, it’s important to understand the role they plan in severe asthma. Join us as we discuss an exploratory study and the role of mucus plugging in severe asthma with Dr. Charles Turck and Professor Arnaud Bourdi…

1
Reducing the Disease Burden of AML with Vor Bio's Dr. Robert Ang 23:08

5M ago23:08

23:08

We love to hear from our listeners. Send us a message. In 2021 on Episode 13, Vor Bio’s President and CEO, Dr. Robert Ang shared data about the company’s lead engineered hematopoietic cell (eHSC) product candidate. Dr. Ang is back to talk to Cell & Gene: The Podcast Host, Erin Harris, about how Vor has treated 8 patients demonstrating clinical proo…

1
Against the Odds: Improving Survival for Children with Pulmonary Vein Stenosis

5M ago

—

Guest: Christopher Petit, MD Pulmonary vein stenosis (PVS) is a rare and challenging heart condition, which narrows blood vessels around the lungs and typically impacts newborn children. Historically, the rates of survival have been low, but with Dr. Petit leading the development of innovative techniques and treatments, the trajectory of patients’ …

1
The Network Effect: Analyzing Brain Structures to Treat Depression

5M ago

—

Guest: Conor Liston, MD, PhD For patients diagnosed with depression for the first time the recommended course of treatment is the same; however, there’s a large patient population for whom these treatments won’t work. So it became increasingly important for Dr. Liston to map the brains of people suffering from major depression to see how it was imp…

1
Oncology Today with Dr Neil Love: The Emerging Role of B7-H3-Targeted Antibody-Drug Conjugates 32:24

5M ago32:24

32:24

Dr Manish Patel from the Florida Cancer Specialists & Research Institute in Sarasota, Florida, discusses drug development, early-phase clinical trials and the emerging field of B7-H3-targeted antibody-drug conjugates for solid tumors.By Neil Love, MD

1
Homologous Recombination Repair (HRR) Testing and Targeted Therapy in Prostate Cancer 48:15

5M ago48:15

48:15

In this episode, Colin C. Pritchard, MD, PhD, a pathologist, and Heather H. Cheng, MD, PhD, a medical oncologist, discuss optimal biomarker testing to guide treatment decisions in advanced prostate cancer, with topics including: Rationale for targeting PARP in prostate cancer with ARI combinations Study design nuances and findings from key randomiz…

1
Reducing Toxicities in Allogeneic Cell Therapies with Orca Bio's Dr. Scott McClellan 19:37

5M ago19:37

19:37

We love to hear from our listeners. Send us a message. Orca Bio's CMO, Dr. Scott McClellan, joins Erin Harris on this episode of Cell & Gene: The Podcast to discuss how and why toxicities continue to stymie allogeneic cell therapies. They cover Orca Bio's plan to potentially lowering the risk of GvHD as well as Orca-T, the investigational high-prec…

1
Addressing Treatment Gaps Among Patients with MDS-Associated Anemia

5M ago

—

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Jamie Koprivnikar, MD Patients with lower-risk myelodysplastic syndromes (MDS) lack treatment options, specifically in treating anemia. However, the FDA approval of Reblozyl (luspatercept-aamt) as a first-line therapy for treating anemia in ESA-naïve patients with lower-risk MDS presents an option for…

1
Oncology Today with Dr Neil Love: Promising Therapeutic Strategies for Patients with Progressive Metastatic Non-Small Cell Lung Cancer 1:02:57

6M ago1:02:57

1:02:57

Dr Melissa Johnson from Sarah Cannon Research Institute in Nashville, Tennessee, discusses available data with antibody-drug conjugates with established and investigational targets in patients with non-small cell lung cancer.By Neil Love, MD

Podcasts Worth a Listen

Current Therapeutic Updates Podcasts

Podcasts Worth a Listen

Quick Reference Guide